Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.07 CAD | +7.69% | +7.69% | -41.67% |
Mar. 13 | Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations | MT |
Feb. 29 | Sirona Biochem Corp. Reports Earnings Results for the Full Year Ended October 31, 2023 | CI |
Sales 2022 | 672K 494K | Sales 2023 | 34.78K 25.58K | Capitalization | 21.44M 15.77M |
---|---|---|---|---|---|
Net income 2022 | -3M -2.21M | Net income 2023 | -2M -1.47M | EV / Sales 2022 | 48.8 x |
Net Debt 2022 | 48.04K 35.33K | Net Debt 2023 | 1.61M 1.18M | EV / Sales 2023 | 663 x |
P/E ratio 2022 |
-8.81
x | P/E ratio 2023 |
-8.43
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.35% |
1 day | -7.14% | ||
1 week | -7.14% | ||
Current month | -23.53% | ||
1 month | -27.78% | ||
3 months | -45.83% | ||
6 months | -38.10% | ||
Current year | -45.83% |
Managers | Title | Age | Since |
---|---|---|---|
Howard Verrico
CEO | Chief Executive Officer | - | 06-10-18 |
Director of Finance/CFO | - | 09-04-28 | |
Chief Tech/Sci/R&D Officer | - | 11-03-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Howard Verrico
CEO | Chief Executive Officer | - | 06-10-18 |
Alex Marazzi
BRD | Director/Board Member | - | 06-10-18 |
Director of Finance/CFO | - | 09-04-28 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.07 | +7.69% | 1 000 |
24-03-27 | 0.065 | -7.14% | 17,000 |
24-03-26 | 0.07 | -6.67% | 14,020 |
24-03-25 | 0.075 | -6.25% | 7,555 |
24-03-22 | 0.08 | +23.08% | 22,721 |
Delayed Quote Toronto S.E., March 27, 2024 at 02:06 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-45.83% | 12.2M | |
+9.16% | 45.97B | |
+53.75% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |